-
Recent Posts
- December 01 2013 – Human stem cells converted to functional lung cells
- November 30 2013 – Keyhole lung transplant performed on 60-year-old in Chennai
- November 27 2013 – FibroGen Announces Observations of Possible Disease Stabilization and Improvement in Interim Analysis of Phase 2 Study of FG-3019
- November 15 2013 – Enzo Biochem Announces Study in Leading Scientific Journal Linking Idiopathic Pulmonary Fibrosis, a Deadly Human Disease with No Effective Treatment Options, to Presence of a Monkey Virus
- November 10 2013 – Research by Saint Louis University scientists offers way to disrupt fibrosis
Recent Comments
- Fish With Captain Frank on June 20 2012 MicroDose Therapeutx and Moerae Matrix Announce Collaboration to Develop Novel Inhaled Treatment for Idiopathic Pulmonary Fibrosis (IPF)
- Raymond on June 9 2011 – Ascend Trial – Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Johng182 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- Johnf73 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- extreme rush on June 28 2012 Grasping at Straws while Gasping for Air
Archives
Categories
Meta
Monthly Archives: September 2013
September 2 2013 – New pathway to treat colorectal cancer, pulmonary fibrosis
Israel researchers uncover secrets of how a certain white blood cell can flip from being a ‘good guy’ to a ‘bad guy’ in diseases with no current cure. Doctoral student Danielle Karo-Atar studying macrophages at Tel Aviv University. A type … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
September 2 2013 – Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial, and their respiratory pipeline products in COPD, asthma, IPF and lung cancer at ERS 2013
INGELHEIM, Germany–(BUSINESS WIRE)– For media outside the UK, US and Canada Results of COPD Phase III landmark trial TIOSPIR™comparing safety and efficacy of SPIRIVA® Respimat® versus SPIRIVA® HandiHaler® Phase III trial results on investigational compound olodaterol* Respimat® as once-daily maintenance bronchodilator monotherapy in COPD … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
August 8 2013 – Aradigm Awarded NIH Grant to Investigate New Methods of Diagnoses of Aspirations of Gastrointestinal Contents into the Respiratory Tract with Scientists at UC San Francisco
HAYWARD, Calif.–(BUSINESS WIRE)– The National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), awarded Aradigm Corporation (ARDM) a Small Business Initiative Research (SBIR) grant to investigate the development and validation of tests for gastro-esophageal reflux with aspirations into … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
August 5 2013 – Oral N-acetylcysteine (NAC) reduces COPD exacerbations in RCT (Chest)
Oxidative stress (imbalance between oxidants and antioxidants) is part of the story of how COPD causes symptoms of cough and shortness of breath. Cigarette smoke is the main source of oxidation damage in the lungs leading to COPD, but even … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
August 3 2013 – Ambrisentan found ineffective against idiopathic pulmonary fibrosis
1. Ambrisentan is ineffective in delaying disease progression in idiopathic pulmonary fibrosis (IPF). 2. Compared to placebo, Ambrisentan is associated with increased risk of disease progression and respiratory hospitalization. Evidence rating level: 1 (Excellent) Study rundown: Idiopathic Pulmonary Fibrosis (IPF) is … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Interstitial Lung Disease, IPF, Lung Transplant, Medical, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
July 29 2013 – UVM hosts conference on revolutionary cell therapies to treat deadly lung diseases
On Monday, July 29, 2013, leading lung disease researchers from around the globe will participate in the fifth biennial “Stem Cells and Cell Therapies in Lung Biology Conference” at the University of Vermont (UVM). Since the meeting’s initiation eight years … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
July 15 2013 – Compugen Announces US Patent Allowance for Drug Candidate Recently Presented at 2013 American Thoracic Society Meeting
Compugen Ltd. (NASDAQ: CGEN [FREE Stock Trend Analysis]) announced today that the company has received an Issue Notification from the U.S. Patent and Trademark Office for a patent application covering the company’s drug candidate CGEN-25009. CGEN-25009 is intended for the … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
July 11 2013 – ProMetic’s Lead Drug Candidate, PBI-4050, on Track to Enter Clinical Trial Program in September 2013
LAVAL, QUEBEC–(Marketwired – July 11, 2013) – ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF), (“ProMetic” or the “Corporation”) announced today that its lead drug candidate PBI-4050, is on track to enter the clinical trial program starting in September 2013. During the … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
July 7 2013 – University of Washington’s first double lung transplant doing great 2 decades later
The first person to get a double lung transplant at the University of Washington is still breathing strong 20 years later. Ken Price had been living with cystic fibrosis since he was 1 year old, KOMO-TV reports. He was the … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
July 2 2013 – New procedure to treat acid reflux can prevent chronic rejection in lung transplant patients
A Loyola University Medical Center study suggests that a procedure to treat acid reflux could help prevent chronic rejection in lung transplant patients. The study also found that certain proteins found in lung fluid can help predict whether a patient’s … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment